SPRAVATO® Treatment in Gilbert, AZ: What It Is, How It Works, and Who Qualifies
The U.S. Food and Drug Administration approved SPRAVATO® as the first nasal spray treatment for treatment-resistant depression in 2019, introducing a mechanism of action that standard antidepressants do not share (U.S. Food and Drug Administration). SPRAVATO® contains esketamine, a form of ketamine developed specifically for clinical treatment of depression. At Core Self in Gilbert, we offer SPRAVATO® under REMS-certified protocols, and this is what the treatment involves.
What SPRAVATO® Is and How It Differs From Standard Antidepressants
SPRAVATO® contains esketamine, a derivative of ketamine with a long history of medical use that has become one of the most closely studied compounds in psychiatric research. SPRAVATO® is delivered as a nasal spray and is specifically designed for clinical administration under medical supervision. It is distinct from IV ketamine infusions and recreational use of the compound, which differ from SPRAVATO® in dose, administration route, clinical setting, and regulatory framework. Core Self offers SPRAVATO® and does not offer IV ketamine infusions.
What makes SPRAVATO® clinically significant is where it acts in the brain. Standard antidepressants, including SSRIs and SNRIs, work primarily on the serotonin and norepinephrine systems. For patients whose depression involves neurological pathways those medications do not address, standard antidepressants often produce limited results. SPRAVATO® operates through the glutamate system, the brain's primary excitatory neurotransmitter network, targeting NMDA receptors in a way that produces changes in brain function that can occur much faster than with conventional medications (National Institutes of Health).
If you are interested in how ketamine-based treatments fit into the broader landscape of depression care, our post on ketamine treatments for depression provides helpful context alongside what SPRAVATO® specifically offers.
How SPRAVATO® Works in the Brain
NMDA receptors are part of the glutamate system and play a central role in synaptic plasticity, the brain's ability to strengthen and form connections between neurons (National Institutes of Health). In patients with depression, this plasticity is often impaired. SPRAVATO®'s action at these receptors can rapidly restore the signaling capacity involved in mood regulation.
The result for many patients is a speed of symptom relief unlike what standard antidepressants produce. SSRIs and SNRIs typically require weeks before any clinical effect becomes noticeable. SPRAVATO®'s mechanism allows for faster onset, which is one reason it became the first monotherapy approved for treatment-resistant depression in the United States (Johnson & Johnson).
This does not mean SPRAVATO® works the same way for everyone. Results vary by individual, and the degree and duration of response depend on factors that a thorough clinical evaluation helps identify before treatment begins.
Who Qualifies for SPRAVATO® at Core Self
SPRAVATO® is FDA-approved for two specific indications: treatment-resistant depression in adults, and major depressive disorder with suicidal thoughts or actions in adults. Treatment-resistant depression is clinically defined as a major depressive episode that has not responded adequately to at least two antidepressant medications at therapeutic doses for a sufficient duration.
SPRAVATO® must be used in combination with an oral antidepressant. It is not a standalone replacement for all other psychiatric care. Patients are evaluated carefully before treatment begins, and not everyone who inquires will be an appropriate candidate. Contraindications exist and are reviewed during the clinical assessment.
Our evaluation reviews your full psychiatric and medical history, your prior antidepressant trials, and any other factors relevant to whether SPRAVATO® is appropriate for your situation. We conduct this evaluation before making any recommendation.
What a SPRAVATO® Session Looks Like
SPRAVATO® is self-administered by the patient under direct clinical supervision at our office in Gilbert. You use the nasal spray device yourself while your provider monitors you on-site. No injection or external procedure is performed.
Treatment begins with an induction phase of one to two sessions per week during the first several weeks. Your provider assesses your response throughout and transitions you to a maintenance schedule based on your individual progress and goals. Each session requires an on-site monitoring period of approximately two hours after the dose is administered. You will not be able to drive yourself home after a session, so a trusted person needs to be available for transportation.
The monitoring period is a built-in component of REMS, or Risk Evaluation and Mitigation Strategy, the FDA-required program that governs SPRAVATO® treatment. REMS protocols exist to ensure patient safety in the clinical setting, and our team is REMS-certified.
Insurance, Cost, and How to Get Started
SPRAVATO® is covered by most major insurance plans. Our team verifies benefits and handles prior authorization before your first appointment, so you understand your coverage before committing to any treatment. For questions about how SPRAVATO® fits alongside other aspects of your psychiatric care, our medication management team reviews your full medication history as part of the evaluation.
If you have been searching for ketamine treatment in Gilbert, SPRAVATO® may be what you are looking for. It is the FDA-approved, clinically supervised treatment available at Core Self, designed specifically for adults with treatment-resistant depression. The first step is a free consultation, and we encourage every patient to discuss their options fully with their provider before making any decisions. Contact us at (520) 346-0831 or book online to start that conversation.
For patients interested in how SPRAVATO® can be used alongside talk therapy, we cover this in our earlier post on SPRAVATO® and psychotherapy.
Frequently Asked Questions
Is SPRAVATO® the same as ketamine infusions?
No. SPRAVATO® is an FDA-approved nasal spray containing esketamine. IV ketamine infusions are a separate treatment category that Core Self does not offer. SPRAVATO® is self-administered as a nasal spray under clinical supervision following REMS-certified protocols. The dose, route of administration, clinical setting, and regulatory requirements are all different from IV ketamine infusions.
How soon might I notice results with SPRAVATO®?
Some patients report symptom improvement within hours of their first or second session. Others notice changes over the course of the induction phase. Because SPRAVATO® acts through the glutamate system rather than the serotonin system, it can produce results faster than conventional antidepressants for many patients. Results vary by individual, and not every patient will respond in the same way or on the same timeline.
Do I have to stop my current antidepressant to take SPRAVATO®?
No. SPRAVATO® is specifically approved for use alongside an oral antidepressant, not as a replacement for one. Your provider will review your current medications as part of the evaluation and discuss how they factor into your treatment plan.
How long does the treatment protocol last?
Treatment begins with an induction phase of one to two sessions per week for the first several weeks. Your provider adjusts the schedule to a maintenance phase based on your individual response. The plan is reviewed throughout treatment and modified as needed. There is no single fixed endpoint that applies to every patient.
Is SPRAVATO® right for me if my depression is severe?
SPRAVATO® is approved for adults with treatment-resistant depression and for adults with major depressive disorder with suicidal thoughts or actions. If your depression is severe and has not responded to standard medications, you may fall within the population the treatment was designed for. The clinical evaluation is how that determination is made. Call us at (520) 346-0831 to begin that process.
Key Takeaways
SPRAVATO® is an FDA-approved nasal spray containing a form of ketamine developed specifically for clinical use in depression treatment. It is distinct from IV ketamine infusions, which Core Self does not offer.
SPRAVATO® works through the glutamate system at NMDA receptors, which allows it to produce antidepressant effects faster than conventional medications for many patients.
At Core Self, SPRAVATO® is available for adults with treatment-resistant depression and major depressive disorder with suicidal thoughts or actions, used in combination with an oral antidepressant.
Each session involves self-administration of the nasal spray under clinical supervision and a two-hour on-site monitoring period. Patients need a driver after each session.
Results vary by individual. SPRAVATO® is covered by most major insurance plans. Our team verifies coverage before treatment begins.
Conclusion
SPRAVATO® is a meaningful option for adults with treatment-resistant depression, and at Core Self in Gilbert, it is delivered within a whole-person care model that places it in context with your full psychiatric picture. If you have tried antidepressants and are still looking for relief, a conversation with one of our providers is a reasonable next step. Call us at (520) 346-0831 or book your free consultation online to find out whether SPRAVATO® is appropriate for your situation.
References
U.S. Food and Drug Administration. FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
Johnson & Johnson. SPRAVATO® Approved in the U.S. as the First and Only Monotherapy for Adults With Treatment-Resistant Depression. https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression
National Institutes of Health. Ketamine: NMDA Receptors and Beyond. https://pmc.ncbi.nlm.nih.gov/articles/PMC5148235/
Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. SPRAVATO® is an FDA-approved treatment available at Core Self for adults who meet clinical criteria following a thorough psychiatric evaluation. Individual results vary. SPRAVATO® is not appropriate for every patient, and treatment decisions should only be made under the supervision of a qualified psychiatric provider familiar with your full medical and mental health history. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.
